Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is a global biotechnology company focused on hereditary angioedema (HAE) and other rare diseases, and its news flow reflects this specialization. Company press releases frequently highlight regulatory milestones, clinical data, commercial performance, and strategic transactions related to its flagship product ORLADEYO® (berotralstat) and its broader rare disease pipeline.
Investors following BCRX news can expect regular updates on ORLADEYO, described as the first oral, once-daily plasma kallikrein inhibitor for prophylaxis to prevent HAE attacks. Recent announcements have covered U.S. Food and Drug Administration approval of an oral pellet formulation for pediatric patients aged 2 to <12 years, interim data from the APeX-P pediatric trial showing early and sustained reductions in attack rates, and presentations at major allergy and immunology congresses on the burden of HAE in children and caregivers.
BioCryst also issues news on its financial outlook and operating performance, including preliminary ORLADEYO net revenue, total revenue guidance that incorporates RAPIVAB® (peramivir injection), and non-GAAP operating expense expectations. These releases often explain how structural changes, such as the sale of the European ORLADEYO business, affect the company’s revenue mix and cost base.
Strategic and corporate developments are another major theme in BCRX news. The company has announced a definitive agreement to acquire Astria Therapeutics, Inc., with updates on regulatory clearances such as early termination of the Hart-Scott-Rodino waiting period and expected closing timelines. Additional news items include leadership changes, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and planned presentations at high-profile investor conferences.
For readers tracking BCRX, this news stream offers insight into BioCryst’s commercial execution in HAE, progress of its rare disease pipeline, evolving capital allocation, and key corporate events. Regularly reviewing these updates can help contextualize movements in BCRX stock and provide a clearer picture of the company’s strategic direction.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its upcoming presentation at the Cantor Global Healthcare Conference in New York. The presentation is scheduled for Thursday, September 4, 2025, at 9:45 a.m. ET. Investors can access both the live audio webcast and replay through the Investors & Media section of BioCryst's website.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that Dr. Helen Thackray, Chief Research and Development Officer, will depart the company on September 1, 2025, transitioning to an advisory role through year-end. Dr. Thackray, who joined as a board member in 2019 and became R&D chief in 2021, was a finalist in the recent CEO succession process.
Under her leadership, BioCryst achieved significant milestones, including launching the KLK5 inhibitor BCX17725 for Netherton syndrome, advancing the avoralstat program for diabetic macular edema, and bringing the ORLADEYO pediatric program close to market approval. Dr. Thackray is departing to pursue a chief executive leadership opportunity elsewhere.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced the granting of stock options and restricted stock units (RSUs) to 10 newly-hired employees as employment inducements. The compensation committee approved options to purchase 36,700 shares and RSUs covering 89,750 shares of common stock.
The options were granted with an exercise price of $7.95 per share, matching BioCryst's closing price on August 1, 2025. Both options and RSUs will vest over four equal annual installments, starting one year from the grant date, with options having a 10-year term. These grants were made under BioCryst's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
BioCryst Pharmaceuticals (Nasdaq:BCRX) reported outstanding Q2 2025 financial results, marking the company's best quarter historically. ORLADEYO net revenue reached $156.8 million, up 45% year-over-year, with total revenues of $163.4 million. The company achieved an operating profit of $29.8 million (+239% y-o-y) and non-GAAP operating profit of $57.0 million.
Key highlights include record-breaking new patient prescriptions, increased prescriber base, and lower discontinuation rates. BioCryst made a $50 million debt paydown in July and plans to retire all remaining term debt using proceeds from the sale of its European ORLADEYO business. The company maintains its 2025 ORLADEYO revenue guidance of $580-600 million and expects positive cash flows for the full year.
The rare disease pipeline continues advancing with ORLADEYO granules for children (PDUFA date: December 12, 2025) and expected initial data from BCX17725 and avoralstat programs by year-end.BioCryst Pharmaceuticals (Nasdaq: BCRX) announced a significant leadership transition as CEO Jon Stonehouse plans to retire on December 31, 2025. Charlie Gayer, the company's current Chief Commercial Officer, will assume the role of president on August 1, 2025, and become CEO on January 1, 2026.
Gayer has been instrumental in the successful launch of ORLADEYO®, the company's oral prophylactic therapy for hereditary angioedema, which is expected to achieve peak sales of $1 billion. He also played a key role in the planned sale of BioCryst's European operations. Gayer joined BioCryst in 2015 and brings extensive experience from leadership roles at Talecris Biotherapeutics, Grifols, and GlaxoSmithKline.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has scheduled its second quarter 2025 financial results announcement for Monday, August 4, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update.
Investors can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international). A live webcast and replay will be available in the investors section at www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in the 2025 US HAEA National Summit in Baltimore from July 10-13, 2025. The company will present three research posters focusing on HAE treatments, including patient perspectives, treatment burden on pediatric patients under 12 and their caregivers, and attack rates in pediatric patients using prophylactic berotralstat.
CEO Jon Stonehouse emphasized the company's decade-long commitment to the HAE patient community and highlighted BioCryst's achievement in developing the first oral, once-daily prophylactic therapy for HAE in adults and adolescents. Stonehouse will deliver a corporate presentation during the summit.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has appointed Babar Ghias as Chief Financial Officer and Head of Corporate Development. Ghias joins from AvenCell Therapeutics, where he served as CFO since 2022, bringing significant experience in deal-making and operations in rare disease companies.
Throughout his career, Ghias has raised over $1 billion in capital and completed over $80 billion in transactions as an investment banker at Credit Suisse. His previous roles include executive positions at Paragon Biosciences, where he launched four biotechnology companies, and CFO at Marathon Pharmaceuticals, where he led the company's successful sale.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced the granting of restricted stock units (RSUs) to eight newly-hired employees. The compensation committee approved a total of 57,000 shares of BioCryst common stock as inducement awards on July 1, 2025.
The RSUs will vest over four years in equal annual installments, starting from the one-year anniversary of the grant date, contingent on continued employment. These grants were made under Nasdaq Listing Rule 5635(c)(4) and are subject to BioCryst's Inducement Equity Incentive Plan terms.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has agreed to sell its European ORLADEYO® business to Neopharmed Gentili for up to $264 million, comprising a $250 million upfront payment and up to $14 million in future milestones.
The company plans to use the proceeds to retire its remaining $249 million term debt from Pharmakon, eliminating approximately $70 million in future interest payments. BioCryst expects to end 2027 with approximately $700 million in cash and no term debt, representing a $400 million increase from prior guidance.
The transaction, expected to close by early October, includes the transfer of BioCryst's European organization to Neopharmed Gentili, resulting in projected annual operating expense savings of at least $50 million for BioCryst.
FAQ
What is the current stock price of Biocryst Pharmaceuticals (BCRX)?
What is the market cap of Biocryst Pharmaceuticals (BCRX)?
